Maine’s Medical Cannabis Program Faces Regulatory Pressure Amid Tracking and Contamination Concerns

Maine’s renowned medical cannabis program, lauded for its patient-driven and small-scale caregiver model, is now under intense pressure from a confluence of regulatory changes, contamination concerns, and the potential imposition of a powerful seed-to-sale tracking system. For decades, the state has fostered a unique environment where caregivers—often operating as microbusinesses—provide cannabis directly to patients, many of whom rely on trusted, locally grown products. This decentralized approach has allowed the program to flourish, with over 112,000 registered patients in 2025, representing nearly 8% of Maine’s population and one of the highest per-capita rates nationally

The introduction of METRC, a seed-to-sale tracking system widely used in adult-use markets, has become a flashpoint in the debate over the future of Maine’s medical cannabis sector. Regulatory authorities, armed with contamination studies and public health backing, are pushing for stricter oversight, including METRC’s mandatory tracking and expanded testing requirements. Critics argue that such measures threaten to upend the low-barrier, trust-based framework that has defined the state’s medical marijuana landscape for over 25 years. "We have by far the highest quality regulatory environment for our medical cannabis program, as evidenced by the amazing number of participants True craft businesses, true micro businesses, all the things that folks like to point out as what we should be supporting—Maine is already doing it and has been doing it since ’99," said Mark Barnett, founder and policy director of the Maine Craft Cannabis Association

Historically, Maine’s medical cannabis system has operated under agricultural-style regulations with paper recordkeeping, minimal mandatory testing, and direct oversight by state authorities. Caregivers like Lizzy Hayes, who operates an off-grid, organic-certified farm, highlight that existing regulations already require detailed records and allow for audits and inspections. The program’s structure has enabled caregivers to thrive, with 1,539 caregivers and over 5,000 employees supported by medical cannabis sales that have consistently outperformed the adult-use market. In 2023, medical cannabis sales still surpassed recreational sales, generating $280 million compared to $217 million

The regulatory landscape began to shift following Maine’s 2016 legalization of recreational cannabis, which brought in consultants—including future METRC executives—to draft new rules. The adult-use framework introduced mandatory METRC tracking and rigorous batch testing, with compliance costs accumulating through monthly fees and RFID tag charges. While the medical program remained separate, recent moves by the Office of Cannabis Policy (OCP) under Director John Hudak have reignited fears that the medical sector will be forced into the same mold. Hudak’s expanded contract with METRC, valued at $890,000, drew scrutiny for potential conflicts of interest and for contradicting legislative efforts intended to limit METRC’s influence

Amid these developments, advocates succeeded in passing LD 1242, a law designed to prevent rule changes to the medical program without transparent legislative input. However, many in the community now fear that this protection is being eroded, as regulatory and executive actions continue to favor large-scale compliance systems over the caregiver model. “Like so much stuff in cannabis, the disaster and the damage isn’t in the statute that enables it. It’s in the rule,” Barnett explained, emphasizing the impact of administrative decisions over legislative intent

From the OG Lab newsroom perspective, Maine’s unfolding regulatory battle highlights a broader tension in the cannabis industry between grassroots, patient-focused operations and the push for centralized, technology-driven oversight. The outcome will have significant implications for small businesses and patient access, both in Maine and as a precedent for other states. This situation is worth monitoring closely as it may determine whether craft cannabis models can survive in an era of increasing regulation and industry consolidation